SCHEMBL22917040

SCHEMBL22917040

COC(=O)c1cc2c(n1Cc1ccc(C(C)C)cc1)CCCC2=O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.43
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 8/20 0.42
TSHR P16473 1/20 0.42
TP53 P04637 3/20 0.41
HRH3 Q9Y5N1 1/20 0.41
THRB P10828 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
PTGS2 P35354 1/20 0.39
HPGD P15428 1/20 0.38
ACACB O00763 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23174927 0.87 BRD4 (0.49) BRD4L3MBTL1GAANPSR1MAPT
SCHEMBL21423952 0.87 L3MBTL1 (0.57) BRD4L3MBTL1GAANPSR1MAPT
SCHEMBL25514686 0.87 BRD4 (0.43) BRD4NPSR1MAPTTP53HRH3
SCHEMBL21410171 0.85 BRD4 (0.50) BRD4L3MBTL1GAANPSR1MAPT
SCHEMBL25514682 0.85 BRD4 (0.41) BRD4L3MBTL1GAANPSR1MAPT
SCHEMBL21410129 0.82 BRD4 (0.44) BRD4L3MBTL1GAANPSR1MAPT
SCHEMBL25514004 0.81 BRD4 (0.52) BRD4NPSR1MAPTTSHRHRH3
SCHEMBL29521197 0.79 BRD4 (0.42) BRD4L3MBTL1GAANPSR1MAPT
SCHEMBL22916953 0.79 BRD4 (0.73) BRD4NPSR1MAPTTSHRTP53
SCHEMBL22917038 0.76 BRD4 (0.52) BRD4L3MBTL1GAANPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 BRD4 2025/4885L3MBTL1 631/4885GAA 264/4885
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 BRD4 2025/4885L3MBTL1 631/4885GAA 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.